Literature DB >> 33971147

Safety and Performance of Transbronchial Cryobiopsy for Parenchymal Lung Lesions.

Felix J Herth1, Max Mayer2, Jeffrey Thiboutot3, Christopher M Kapp3, Jiayuan Sun4, Xiaoju Zhang5, Jonas Herth6, Konstantina Kontogianni1, Lonny Yarmus7.   

Abstract

BACKGROUND: Despite advances in technology, the bronchoscopic diagnosis of parenchymal pulmonary lesions (PPLs) remains difficult to achieve. Transbronchial lung cryobiopsy (TLCB) offers the potential for larger samples with improved diagnostic yield; however, a paucity of data exists describing its safety and usefulness for the diagnosis of PPL. RESEARCH QUESTION: What is the safety profile of TLCB for PPL? STUDY DESIGN AND METHODS: An observational, retrospective, multicenter cohort study enrolled patients without endobronchial disease undergoing TLCB of PPL from 2015 through 2019. All procedures were performed using both rigid and flexible bronchoscopy with a flexible cryoprobe. Complication rates, including bleeding and pneumothorax rates, were collected. Bleeding was graded on a scale from 0 (trace) to 4 (requiring surgical intervention) with a grade of ≥ 3 considered clinically significant. Pneumothorax, tube thoracostomy placement, diagnostic yield, and need for subsequent interventions were recorded.
RESULTS: One thousand twenty-four patients underwent TLCB. One hundred eighty-eight patients (18%) experienced bleeding; in 36 patients (3.5%), the bleeding was clinically significant. Sixty-eight patients (6.6%) demonstrated a pneumothorax and 64 patients (6.3%) required drainage with tube thoracostomy. All chest drains were removed within 4 days, and no cases of prolonged air leak occurred. A definitive diagnosis was achieved in 932 patients (91%). Adenocarcinoma (46%) and metastatic disease (21%) were the most common diagnoses.
INTERPRETATION: TLCB showed an acceptable safety profile and diagnostic yield for the evaluation of PPL in this large retrospective cohort. Prospective clinical trials are underway to validate these findings further.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bronchoscopy; cryobiopsy; lung cancer; peripheral pulmonary lesions

Mesh:

Year:  2021        PMID: 33971147     DOI: 10.1016/j.chest.2021.04.063

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Alternative methods for local ablation-interventional pulmonology: a narrative review.

Authors:  Gerard Olive; Rex Yung; Henry Marshall; Kwun M Fong
Journal:  Transl Lung Cancer Res       Date:  2021-07

2.  ERS International Congress 2021: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly.

Authors:  Christina Bal; Casper Falster; Andre Carvalho; Nicole Hersch; Judith Brock; Christian B Laursen; Simon Walsh; Jouke Annema; Daniela Gompelmann
Journal:  ERJ Open Res       Date:  2022-05-23

3.  Efficacy and Safety of Cryobiopsy vs. Forceps Biopsy for Interstitial Lung Diseases, Lung Tumors, and Peripheral Pulmonary Lesions: An Updated Systematic Review and Meta-Analysis.

Authors:  Mohan Giri; Guichuan Huang; Anju Puri; Rongjuan Zhuang; Yishi Li; Shuliang Guo
Journal:  Front Med (Lausanne)       Date:  2022-03-10

4.  Air embolism after transbronchial lung cryobiopsy: A case report.

Authors:  Masanori Kawataki; Yosuke Nakanishi; Takashi Niwa; Tadashi Ishida
Journal:  Respirol Case Rep       Date:  2022-09-07

5.  Thin bronchoscopic cryobiopsy using a nasobronchial tube.

Authors:  Masahide Oki; Hideo Saka; Yoshihito Kogure; Hideyuki Niwa; Akane Ishida; Arisa Yamada; Atsushi Torii; Chiyoe Kitagawa
Journal:  BMC Pulm Med       Date:  2022-09-24       Impact factor: 3.320

6.  Diagnostic Yield of Transbronchial Cryobiopsy Guided by Radial Endobronchial Ultrasound and Fluoroscopy in the Radiologically Suspected Lung Cancer: A Single Institution Prospective Study.

Authors:  Vytautas Ankudavicius; Skaidrius Miliauskas; Lina Poskiene; Donatas Vajauskas; Marius Zemaitis
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.